3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
27
Breast Neoplasms
23
Neoplasm Metastasis
14
Glioma
14
Carcinoma, Non-Small-Cell Lung
14
Lymphoma
12
Lung Neoplasms
11
Glioblastoma
11
Neuroblastoma
10
Lymphoma, Non-Hodgkin
9
Carcinoma, Renal Cell
9
Brain Neoplasms
9
Medulloblastoma
8
Ovarian Neoplasms
7
Neoplasms
7
Multiple Myeloma
7
Ependymoma
7
Carcinoma, Hepatocellular
7
Wilms Tumor
6
Thyroid Neoplasms
6
Sarcoma
6
Rectal Neoplasms
6
Pancreatic Neoplasms
6
Osteosarcoma
6
Melanoma
6
Fallopian Tube Neoplasms
6
Central Nervous System Neoplasms
6
Uterine Cervical Neoplasms
5
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Interventions
Paclitaxel
4
pembrolizumab
2
pazopanib
2
efatutazone
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
trametinib
1
tislelizumab
1
surufatinib
1
spartalizumab
1
sapanisertib
1
lenvatinib
1
fosbretabulin
1
dabrafenib
1
crolibulin
1
combretastatin
1
cabozantinib
1
atezolizumab
1
abemaciclib
1
Taxes
1
Imatinib Mesylate
1
Gefitinib
1
Doxorubicin
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
CUDC-907
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Carcinoma, Anaplastic
×
Magnetic Resonance Spectroscopy
×
Clear all
No trials found.